TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28817248

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 14
Study: 27451354

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL) in addition to treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL)
Number of subjects: 0
Study: 24942553

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (EPA:DHA = 0.9:1.5; 9 μM EPA plus 15 μM DHA)
Number of subjects: 20
Study: 24350814

Group type: EXPERIMENTAL
Intervention: Clomipramine (n=9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 30
Study: 20837788

Group type: EXPERIMENTAL
Intervention: Low vision device training (additional appointment for device handling)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (standard low vision assessment without additional training)
Number of subjects: 96
Study: 19463342

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT)
Number of subjects: 0
Study: 16509177

Group type: EXPERIMENTAL
Intervention: Oxygen concentrator
Number of subjects: 10

Group type: COMPARATOR
Intervention: Piped oxygen
Number of subjects: 10
Study: 14499226

Group type: EXPERIMENTAL
Intervention: Countries with the highest tertile of in-hospital revascularization rates (>39%)
Number of subjects: 16949

Group type: COMPARATOR
Intervention: Countries with intermediate tertile of in-hospital revascularization rates (15-39%)
Number of subjects: 16949

Group type: COMPARATOR
Intervention: Countries with the lowest tertile of in-hospital revascularization rates (<15%)
Number of subjects: 16949
Study: 11137414

Group type: EXPERIMENTAL
Intervention: IV diclofenac (0.7 mg/kg bolus followed by 0.15 mg/kg/hr infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (equal volume to diclofenac)
Number of subjects: 40
Study: 9171947

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX) 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (Nal)
Number of subjects: 0
Study: 8268117

Group type: COMPARATOR
Intervention: Lidocaine 1.6% alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.6% with 1% meperidine
Number of subjects: 34
Study: 2445326

Group type: EXPERIMENTAL
Intervention: Krypton laser photocoagulation
Number of subjects: 288

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 288
Study: 30038154

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of retinal length to choroidal length ratio (RCR) before training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of retinal length to choroidal length ratio (RCR) after training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correlation between RCR and interobserver difference
Number of subjects: 50
Study: 26718419

Group type: EXPERIMENTAL
Intervention: Intraduodenal capsaicin infusion (1.5 mg pure capsaicin)
Number of subjects: 13
Study: 25342282

Group type: EXPERIMENTAL
Intervention: Vinflunine
Number of subjects: 102
Study: 23184657

Group type: EXPERIMENTAL
Intervention: Comorbid GAD/MDD group
Number of subjects: 1218

Group type: COMPARATOR
Intervention: MDD group
Number of subjects: 1218

Group type: COMPARATOR
Intervention: GAD group
Number of subjects: 1218
Study: 20492507

Group type: EXPERIMENTAL
Intervention: Mitoquinone (40 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mitoquinone (80 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18096840

Group type: EXPERIMENTAL
Intervention: Aggressive treatment with continuous intravenous insulin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care with subcutaneous insulin QID as needed
Number of subjects: 46
Study: 17199202

Group type: EXPERIMENTAL
Intervention: Anonymous STD counselling and comprehensive services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obligatory VD checks for prostitutes
Number of subjects: 0
Study: 14528773

Group type: EXPERIMENTAL
Intervention: Computerized local anesthesia (Wand)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional syringe injection
Number of subjects: 102
Study: 10599773

Group type: EXPERIMENTAL
Intervention: Metrifonate (30 to 60 mg based on weight or a 50-mg fixed dose)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 959
Study: 8846152

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non supplemented women
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 66
Study: 1663965

Group type: EXPERIMENTAL
Intervention: Lisinopril (average dose 18.8 mg)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine (average dose 37.4 mg)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine (highest dose level)
Number of subjects: 828
Study: 6104172

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), administered three times a week, with a minimum of eight treatments and a maximum of twelve.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no electricity used, no convulsion induced), administered the same treatment procedure as ECT.
Number of subjects: 20
Study: 30998792

Group type: EXPERIMENTAL
Intervention: Mediterranean meal (MdM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fast Food meal (FFM)
Number of subjects: 39
Study: 28401197

Group type: EXPERIMENTAL
Intervention: PRF combined with a new split crest flapless modified technique (test group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional technique with deeper insertion of smaller implants (control group)
Number of subjects: 10
Study: 26010803

Group type: EXPERIMENTAL
Intervention: Modified preparation (300 mg of aspirin and 75 mg of clopidogrel bisulfate; with 200 mg of cilostazol added for HTPR to clopidogrel)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard preparation (100 mg of aspirin and 75 mg of clopidogrel)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Non-HTPR group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Modified preparation
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 228
Study: 24130381

Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and tinidazole for 5 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard therapy (PPI, clarithromycin and amoxicillin for 10 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 2
Study: 21823278

Group type: EXPERIMENTAL
Intervention: Acupoint pressing
Number of subjects: 168

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 168

Group type: COMPARATOR
Intervention: Suxiaojiuxin pill
Number of subjects: 168
Study: 19620926

Group type: EXPERIMENTAL
Intervention: COMB - cold water immersion and active recovery using a cycle ergometer
Number of subjects: 28

Group type: COMPARATOR
Intervention: CONT - cold (12 degrees C) water immersion and hot (38 degrees C) shower
Number of subjects: 28

Group type: COMPARATOR
Intervention: PASS - a passive post-match routine (stretching and leg raise)
Number of subjects: 28
Study: 16696841

Group type: EXPERIMENTAL
Intervention: Individuals with learning disability
Number of subjects: 41

Group type: COMPARATOR
Intervention: Age-matched controls without learning disability
Number of subjects: 41
Study: 15595714

Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB) administered to patients with mild Alzheimer's disease (AD)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Frontal Assessment Battery (FAB) administered to normal controls
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Frontal Assessment Battery (FAB) administered to patients with frontotemporal dementia (FTD)
Number of subjects: 236
Study: 11488449

Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin (900 mg daily divided in three doses for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sulfasalazine (3 gm daily divided in three doses for 6 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 30
Study: 9131764

Group type: EXPERIMENTAL
Intervention: Bayesian and mixed Bayesian/likelihood approaches to sample size calculations
Number of subjects: 0
Study: 8097788

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), 60 mg biweekly via System 22 nebulizer
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 209
Study: 3307496

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment specific for substance abuse
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control patients received nonspecific points
Number of subjects: 54
Study: 29125197

Group type: EXPERIMENTAL
Intervention: Active RF‐EMF exposure (902‐928 MHz spread spectrum digitally modulated signal, average radiated power output of 1 W)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham RF‐EMF exposure
Number of subjects: 3
Study: 28171220

Group type: EXPERIMENTAL
Intervention: LaVita® (micronutrient supplementation)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 26553684

Group type: EXPERIMENTAL
Intervention: PsA‐TT
Number of subjects: 1240

Group type: COMPARATOR
Intervention: PsACWY
Number of subjects: 1240
Study: 22926800

Group type: EXPERIMENTAL
Intervention: Intracervical block with premedication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Premedication alone (Control)
Number of subjects: 100
Study: 21920208

Group type: EXPERIMENTAL
Intervention: 5% enflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1.2 mg/kg propofol
Number of subjects: 0
Study: 19001327

Group type: EXPERIMENTAL
Intervention: Concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b
Number of subjects: 395

Group type: COMPARATOR
Intervention: Cisplatin, vinblastine, and dacarbazine (CVD) alone
Number of subjects: 395
Study: 16686228

Group type: EXPERIMENTAL
Intervention: Tracheostomy with culture from the internal trachea wall
Number of subjects: 40
Study: 12506086

Group type: EXPERIMENTAL
Intervention: 2% ibopamine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% tropicamide
Number of subjects: 30
Study: 10547510

Group type: EXPERIMENTAL
Intervention: Glass ionomer bonding system (Fuji Ortho LC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Composite resin bonding system (Reliance Light Bond)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both bonding systems
Number of subjects: 16
Study: 8674322

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Escherichia coli endotoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (with endotoxin)
Number of subjects: 0
Study: 1863928

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Behavioral therapy with the aid of a personal computer
Number of subjects: 168
Study: 6347108

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 125 mg every six hours for three days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 40 mg every six hours for three days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone 15 mg every six hours for three days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High- and medium-dose groups combined
Number of subjects: 25
Study: 28719155

Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment for 7 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control subjects (CS)
Number of subjects: 38
Study: 30672181

Group type: EXPERIMENTAL
Intervention: Methycobal iontophoresis combined with balance acupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Methycobal iontophoresis
Number of subjects: 108

Group type: COMPARATOR
Intervention: Simple balance acupuncture
Number of subjects: 108
Study: 24725329

Group type: EXPERIMENTAL
Intervention: FFT‐CHR (18 sessions over 6 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Enhanced Care (EC; 3 sessions over 1 month)
Number of subjects: 103
Study: 25249568

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg every day
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Elagolix 75 mg twice a day
Number of subjects: 252

Group type: COMPARATOR
Intervention: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Elagolix
Number of subjects: 252

Group type: COMPARATOR
Intervention: DMPA-SC
Number of subjects: 252
Study: 22154867

Group type: EXPERIMENTAL
Intervention: Patient Dialogue (PD)
Number of subjects: 2480

Group type: COMPARATOR
Intervention: Static Patient Information (SPI)
Number of subjects: 2480
Study: 20529142

Group type: EXPERIMENTAL
Intervention: SACMC dressing
Number of subjects: 36

Group type: COMPARATOR
Intervention: AF dressing
Number of subjects: 36
Study: 18611200

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15741771

Group type: EXPERIMENTAL
Intervention: Dose delivered after inhalation of 20% of vital capacity (A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose delivered after inhalation of 70% of vital capacity (B)
Number of subjects: 12
Study: 12424404

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol 50 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoclopramide 0.25 mg/kg
Number of subjects: 120
Study: 9679886

Group type: EXPERIMENTAL
Intervention: Glycine 1.5%
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mannitol 3%
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Irrigant volume increase (1,000 ml)
Number of subjects: 52
Study: 8085380

Group type: EXPERIMENTAL
Intervention: Combined YF/ViPS vaccine (simultaneous administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined YF/ViPS vaccine (combined administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single administration of ViPS vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous administration of ViPS vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined administration of ViPS vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines (simultaneous or combined)
Number of subjects: 0
Study: 2680356

Group type: EXPERIMENTAL
Intervention: Timentin (3.1 g intravenously)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Mezlocillin (2.0 g intravenously)
Number of subjects: 185
Study: 29955820

Group type: EXPERIMENTAL
Intervention: Caregiver-administered ORS fluid monitoring charts
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard care (ORS without charting)
Number of subjects: 252
Study: 27842495

Group type: EXPERIMENTAL
Intervention: EMPOWER-PAR intervention
Number of subjects: 888

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 888
Study: 24637951

Group type: EXPERIMENTAL
Intervention: Diagnosis of COPD
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: COPD duration longer than 5 years
Number of subjects: 1425
Study: 23274782

Group type: EXPERIMENTAL
Intervention: Goal-directed haemodynamic treatment (GDHT) using fluids and dobutamine to attain oxygen delivery index >600 ml min(‐1) m(‐2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Routine fluid treatment (RFT)
Number of subjects: 150
Study: 19952844

Group type: EXPERIMENTAL
Intervention: EGCG (135-mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18729681

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatments
Number of subjects: 393

Group type: COMPARATOR
Intervention: Presence of alcohol dependence (AD)
Number of subjects: 393
Study: 16901645

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF: 12.5 microg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF: 25 microg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB: 35 microg/h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Painful electrical stimulation
Number of subjects: 20
Study: 12897344

Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 1 to ICU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 2 to ICU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Consultants who would admit patient 3 to ICU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Threshold of predicted hospital survival for ICU admission recommendation
Number of subjects: 120
Study: 12112946

Group type: EXPERIMENTAL
Intervention: Treatment of asymptomatic bacterial vaginosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of Trichomonas vaginalis
Number of subjects: 0
Study: 9244940

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine plus saline (group I, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2% mepivacaine plus bicarbonate soda (group II, n = 15)
Number of subjects: 30
Study: 8148226

Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone 17-valerate (suspension in medical grade pressure sensitive adhesive applied to a 100 cm2 area for 28 hours)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral administration of 0.6 mg betamethasone
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical application of betamethasone 17-valerate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oral administration of betamethasone
Number of subjects: 5
Study: 3300292

Group type: EXPERIMENTAL
Intervention: Betaxolol (mean dose of 22 mg for 12 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nadolol (mean dose of 103 mg for 12 weeks)
Number of subjects: 15
Study: 2337121

Group type: EXPERIMENTAL
Intervention: NPH insulin (protamine containing)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lente insulin (protamine free)
Number of subjects: 30
Study: 1105698

Group type: EXPERIMENTAL
Intervention: Reserpine (5 mg i.m.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 14
Study: 31682876

Group type: EXPERIMENTAL
Intervention: Sports/party‐themed ads
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Sports-themed ad
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Party-themed ad
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Control 'product information' ads
Number of subjects: 2010
Study: 30183595

Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 430

Group type: COMPARATOR
Intervention: PBO+MTX
Number of subjects: 430
Study: 28605608

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 25891484

Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23711599

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21293107

Group type: EXPERIMENTAL
Intervention: Daivobet®/Dovobet® gel
Number of subjects: 458

Group type: COMPARATOR
Intervention: Tacalcitol ointment
Number of subjects: 458

Group type: COMPARATOR
Intervention: Gel vehicle alone
Number of subjects: 458
Study: 19466649

Group type: EXPERIMENTAL
Intervention: Elevator metaphor
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Didactic learning
Number of subjects: 42

Group type: COMPARATOR
Intervention: Active learning
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bridge metaphor
Number of subjects: 42
Study: 17269993

Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15238986

Group type: EXPERIMENTAL
Intervention: CPT‐11+gemcitabine (1000 mg m(‐2), days 1 and 8; CPT‐11 300 mg m(‐2), day 8)
Number of subjects: 147

Group type: COMPARATOR
Intervention: CPT‐11 (300 mg m(‐2), day 1)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CPT‐11+gemcitabine
Number of subjects: 147

Group type: COMPARATOR
Intervention: CPT‐11
Number of subjects: 147
Study: 11168509

Group type: EXPERIMENTAL
Intervention: 4G/4G genotype
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: PAI-1 activity
Number of subjects: 198
Study: 9571222

Group type: EXPERIMENTAL
Intervention: 50 mg oral dose of [14C]irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: 900 mg nonradiolabeled doses of irbesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [14C]irbesartan
Number of subjects: 0
Study: 8299334

Group type: EXPERIMENTAL
Intervention: Guidelines for chest radiography dissemination
Number of subjects: 2500
Study: 2455701

Group type: COMPARATOR
Intervention: CVP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: BACOP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Number of subjects: 177
Study: 30117122

Group type: EXPERIMENTAL
Intervention: 50-Hz continuous theta burst stimulation (cTBS50)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30-Hz continuous theta burst stimulation (cTBS30)
Number of subjects: 17
Study: 28506118

Group type: EXPERIMENTAL
Intervention: Fresh coconut (100 g)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Groundnuts and groundnut oil combination
Number of subjects: 58
Study: 26564452

Group type: EXPERIMENTAL
Intervention: Individualized low-protein diet
Number of subjects: 40